Senti Biosciences updates KPMG consent on shelf

Senti Biosciences Holdings, Inc. (SNTI) has filed Amendment No. 3 to its Form S-3 registration statement (File No. 333-296917) solely to add an updated consent from its independent registered public accounting firm, KPMG LLP, as Exhibit 23.1.

Available on EDGAR 09/22/2026 - 06:03 AM EDT Accepted by SEC EDGAR 09/22/2026 - 06:02 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Senti Biosciences Holdings, Inc. (SNTI) has filed Amendment No. 3 to its Form S-3 registration statement (File No. 333-296917) solely to add an updated consent from its independent registered public accounting firm, KPMG LLP, as Exhibit 23.1. The company states that all other parts of the registration statement remain unchanged and are omitted from this amendment.

Filing Explained

The amendment leaves the shelf in a pre-effective state: the company says effectiveness is delayed until a further amendment or SEC determination, so this filing updates an auditor consent but does not itself sell securities.

Key Terms

Registration Statement, exhibits-only filing, Business Combination Agreement, Contingent Value Rights Agreement, +2 more

6 terms

Registration Statement regulatory

"The registrant (the “Registrant”) hereby amends this registration statement"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

exhibits-only filing regulatory

"as an exhibits-only filing to file an updated auditor consent"

Business Combination Agreement financial

"Business Combination Agreement, dated as of December 19, 2021"

A business combination agreement is a detailed contract that lays out the terms for two companies to join together—covering price, how ownership will be split, the steps needed to close the deal, and what each side promises to do or avoid before closing. For investors it matters because the agreement determines potential changes in value, control, timing, and risk exposure—think of it like the playbook for a merger that shows who wins, who pays, and what could still derail the plan.

Contingent Value Rights Agreement financial

"Form of Contingent Value Rights Agreement"

Equity Commitment Letter financial

"Equity Commitment Letter, dated September 3, 2026"

A written promise from an investor or group to provide a specified amount of capital for a deal, such as an acquisition or a new financing round. It matters to investors because it shows how likely a transaction is to close and how much fresh money will be available, similar to a down-payment commitment when buying a house: the stronger the promise, the less risk that the deal will fall apart or that existing shareholders will face unexpected dilution.

Power of Attorney regulatory

"Power of Attorney | | S-3 | | | | 333-296917"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did SNTI change in Amendment No. 3 to its Form S-3?

Amendment No. 3 to Senti Biosciences Holdings, Inc.’s Form S-3 (File No. 333-296917) was filed solely to include an updated auditor consent from KPMG LLP as Exhibit 23.1. The company states that the remainder of the registration statement is unchanged.

Does SNTI’s S-3/A Amendment No. 3 alter the securities being registered?

No. Senti Biosciences Holdings, Inc. explains that this amendment is an exhibits-only filing to add an updated KPMG LLP consent. No changes are made to the substantive terms or disclosure of the underlying registration statement.

Why did SNTI need to file an updated auditor consent on its S-3?

Senti Biosciences Holdings, Inc. is filing Amendment No. 3 to its Form S-3 to provide an updated consent from KPMG LLP, identified as Exhibit 23.1. The company notes this is the sole purpose of the amendment.

Who signed SNTI’s S-3/A Amendment No. 3 on behalf of the company?

The amendment was signed on behalf of Senti Biosciences Holdings, Inc. by Timothy Lu, M.D., Ph.D., as Chief Executive Officer. He also signed as attorney-in-fact for the other directors and the Chief Financial Officer listed in the signature block.

What is the filing date and location associated with SNTI’s S-3/A Amendment No. 3?

Senti Biosciences Holdings, Inc. indicates that the registration statement was signed in South San Francisco, California on September 22, 2026 in connection with this Amendment No. 3.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

As filed with the Securities and Exchange Commission on September 22, 2026

Registration No. 333-296917

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

AMENDMENT NO. 3

TO

FORM S-3

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

SENTI BIOSCIENCES HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware		2836		42-1912154
(State or other jurisdiction of incorporation or organization)		(Primary Standard Industrial Classification Code Number)		(I.R.S. Employer Identification No.)

2 Corporate Drive, First Floor

South San Francisco, CA 94080

(650) 239-2030

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Timothy Lu, M.D., Ph.D.

Chief Executive Officer

Senti Biosciences Holdings, Inc.

2 Corporate Drive, First Floor

South San Francisco, CA 94080

Telephone: (650) 239-2030

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Kirt W. Shuldberg

Keith J. Scherer

Alexa Belonick

Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP

One Bush Plaza, Suite 1200

San Francisco, CA 94104

(858) 436-8000

Approximate date of commencement of proposed sale to the public: From time to time after this Registration Statement becomes effective.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer		☐		Accelerated filer		☐
Non-accelerated filer		☒		Smaller reporting company		☒
				Emerging growth company		☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒

The registrant (the “Registrant”) hereby amends this registration statement, or this Registration Statement, on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until this Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

EXPLANATORY NOTE

Senti Biosciences Holdings, Inc. is filing this Amendment No. 3 (this “Amendment”) to the Registration Statement on Form S-3 (File No. 333-296917) as an exhibits-only filing to file an updated auditor consent as Exhibit 23.1. Accordingly, this Amendment consists only of the facing page, this explanatory note, Item 16 of Part II of the Registration Statement, the signature page to the Registration Statement and the filed Exhibit 23.1. The remainder of the Registration Statement is unchanged and has been omitted.

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 16. Exhibits and Financial Statements Schedules

(a) Exhibits.

				Incorporated by Reference
Exhibit Number		Description		Schedule/Form				File No.				Exhibit				Filing Date
2.1^		Business Combination Agreement, dated as of December  19, 2021, by and among Dynamics Special Purpose Corp., Explore Merger Sub, Inc. and Senti Biosciences, Inc.			S-4/A				333-262707				2.1			May 10, 2022
2.2^		Amendment No. 1 to Business Combination Agreement, dated as of February  12, 2022, by and among Dynamics Special Purpose Corp., Explore Merger Sub, Inc. and Senti Biosciences, Inc.			S-4/A				333-262707				2.2			May 10, 2022
2.3^		Amendment No. 2 to Business Combination Agreement, dated as of May  19, 2022, by and among Dynamics Special Purpose Corp., Explore Merger Sub, Inc. and Senti Biosciences, Inc.			8-K				001-40440				2.1			May 24, 2022
2.4^		Agreement and Plan of Merger, dated April  24, 2026, by and among Senti Biosciences, Inc., Senti Biosciences Holdings, Inc. and Senti Biosciences Merger Sub, Inc.			8-K				001-40440				2.1			April 24, 2026
3.1		Amended and Restated Certificate of Incorporation of Senti Biosciences Holdings, Inc.			8-K				001-40440				3.1			April 24, 2026
3.2		Amended and Restated Bylaws of Senti Biosciences Holdings, Inc.			8-K				001-40440				3.2			April 24, 2026
3.3		Certificate of Merger			8-K				001-40440				3.3			April 24, 2026
3.4		Amended and Restated Bylaws of Senti Biosciences, Inc.			8-K				001-40440				3.2			June 15, 2022
4.1		Specimen Common Stock Certificate			8-K				001-40440				4.1			April 24, 2026
4.2		Form of Senior Secured Convertible Note of Senti Holdings, Inc.			8-K				001-40440				10.1			September 4, 2026
5.1		Opinion of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP			S-3				333-296917				5.1			September 10, 2026
10.1		Securities Purchase Agreement, dated April  27, 2026, by and among Senti Biosciences Holdings, Inc., Senti Holdings, Inc., Senti Biosciences, Inc. and the purchaser named therein			8-K				001-40440				10.1			May 1, 2026

II-1

				Incorporated by Reference
Exhibit Number		Description		Schedule/Form				File No.				Exhibit				Filing Date
10.2		Form of Guarantee			8-K				001-40440				10.3			May 1, 2026
10.3		Form of Registration Rights Agreement by and among Senti Biosciences Holdings, Inc., Senti Biosciences, Inc. and any investor to be named therein			8-K				001-40440				10.4			May 1, 2026
10.4		Form of Voting Agreement by and among Senti Biosciences Holdings, Inc., Senti Biosciences, Inc. and the stockholders to be party thereto			8-K				001-40440				10.5			May 1, 2026
10.5		Amended and Restated Designation Agreement, dated as of April  24, 2026, by and among Senti Biosciences Holdings, Inc., Senti Biosciences, Inc. and Celadon Partners SPV 24			8-K				001-40440				10.1			April 24, 2026
10.6^		Agreement and Plan of Merger, dated as of July  14, 2026, by and among Senti Biosciences Holdings, Inc., Senti Holdings, Inc., Senti Biosciences, Inc., Celadon Partners SPV 35 Limited and Senti Merger Sub, Inc.			8-K				001-40440				2.1			July 15, 2026
10.7		Form of Contingent Value Rights Agreement			8-K				001-40440				10.1			July 15, 2026
10.8		Amendment No. 1 to Securities Purchase Agreement, dated September  1, 2026, by and among Senti Biosciences Holdings, Inc., Senti Holdings, Inc., Senti Biosciences, Inc. and the purchasers named therein			8-K				001-40440				10.1			September 2, 2026
10.9		Equity Commitment Letter, dated September  3, 2026, by and between Senti Biosciences Holdings, Inc. and CPIF II-9 Limited			8-K				001-40440				10.2			September 4, 2026
23.1*		Consent of KPMG LLP, Independent Registered Public Accounting Firm
23.2		Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP			S-3				333-296917				5.1			September 10, 2026
24.1		Power of Attorney			S-3				333-296917				24.1			June 18, 2026
99.1		Unaudited Pro Forma Condensed Consolidated Financial Information			S-3				333-296917				99.1			September 10, 2026
107		Filing Fee Table			S-3				333-296917				107			September 10, 2026

* Filed herewith.

^ Certain exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2). We agree to furnish supplementally a copy of all omitted exhibits and schedules to the Securities and Exchange Commission upon its request.

II-2

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on this Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of South San Francisco, CA on September 22, 2026.

SENTI BIOSCIENCES HOLDINGS, INC.
By:		/s/ Timothy Lu
		Name: Timothy Lu, M.D., Ph.D.
		Title: Chief Executive Officer

II-3

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Signature		Title		Date
* Timothy Lu, M.D., Ph.D.		Chief Executive Officer and Director (Principal Executive Officer)		September 22, 2026
* Jay Cross		Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)		September 22, 2026
* Bryan Baum		Director		September 22, 2026
* James (Jim) Collins, Ph.D.		Director		September 22, 2026
* Brenda Cooperstone, M.D.		Director		September 22, 2026
* Feng Hsiung		Director		September 22, 2026
* Edward Mathers		Director		September 22, 2026
* Frances D. Schulz		Director		September 22, 2026
* Donald Tang		Director		September 22, 2026

*: By: /s/ Timothy Lu, M.D., Ph.D.      

Timothy Lu, M.D., Ph.D.

Attorney-in-Fact

II-4